Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP1 in paediatric medication-resistant epilepsy
ACTRN12618001706268Phase 2Not yet recruiting
- Sponsor
- Cann Pharmaceutical Australia
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing EP1 with Placebo (2 arms). Primary endpoints: Change in seizure frequency and Safety and tolerability. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on ACTRN12618001706268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001706268.